Novartis Expands Zolgensma Manufacturing Capacity With Approval Of Multi-Product North Carolina Facility
Novartis Announced The Us Food And Drug Administration (Fda) Has Granted Commercial Licensure Approval For Its Durham, North California Site, A Multi-Product Gene Therapy Manufacturing Facility. This Approval Allows The State-Of-The-Art, 170,000 Square-Foot Facility To Make, Test And Release Commercial Zolgensma, As Well As Produce Gene Therapy Product For Current And Future Clinical Trials.The Clearance Of This Milestone Brings Online The Second Commercially-Licensed Manufacturing Facility For Novartis Gene Therapies, Joining The Libertyville, Ill. Site, Which Was Approved For Zolgensma (Onasemnogene Abeparvovec) Manufacturing And Distribution In 2019. The Durham Site Will Build On Novartis Gene Therapies
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
